Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients, age 18 years or older, with UC, who within 2 weeks have been started on tofacitinib therapy for moderate to severe UC or who plan to start this therapy within the next 2 weeks. The start of the tofacitinib therapy must have been or be initiated in the setting of standard of care therapy~2. Anticipation that the patient will be followed by the participating center at least for the next 12 months~3. Diagnosis of UC must be established on the basis of standard clinical, radiographic, endoscopic, and histologic criteria as described below.~Exclusion Criteria:~* 1. Patients will be excluded if they meet any of the following criteria:~  1. Inability to provide informed consent~ 2. Patients presenting for a one-time consultation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (Type: None): Adult patients, age 18 years or older, with UC, who within 2 weeks have been started on tofacitinib therapy for moderate to severe UC or who plan to start this therapy within the next 2 weeks. The start of the tofacitinib therapy must have been or be initiated in the setting of standard of care therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).